100
Participants
Start Date
March 19, 2018
Primary Completion Date
August 25, 2021
Study Completion Date
August 25, 2021
continuous glucose monitoring (CGM) iPro™2 Medtronic
A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
University Hospital Centre Zagreb, Zagreb
Collaborators (1)
Takeda
INDUSTRY
Croatian Society for Endocrinology and Diabology
OTHER